Related Experiment Video
Updated: Sep 14, 2025
Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant
Published on: May 27, 2011
Letermovir Prophylaxis Guided by Cytomegalovirus Cell-Mediated Immunity Improves the Outcomes of Allogeneic
Luxiang Wang1, Jingtao Huang1, Chuanhe Jiang1
1Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Background:
The control of cytomegalovirus (CMV) reactivation after allogeneic hematopoietic stem cell transplantation (allo-HSCT) depends heavily on the reconstitution of CMV-specific cell-mediated immunity (CMV-CMI). This study aimed to assess whether CMV-CMI-guided letermovir prophylaxis is more effective than a fixed-duration approach in reducing the incidence of late-onset clinically significant CMV infection (cs-CMVi).
Methods:
This retrospective study included 182 adults who underwent allo-HSCT at 4 participating hospitals. Individuals who received transplantation between June 2022 and April 2023 were treated with a fixed 100-day course of letermovir (fixed-duration group, n = 78), while those receiving transplantation from February 2023 to February 2024 received letermovir based on their CMV-CMI status (CMV-CMI-guided group, n = 104).
Results:
The 1-year cumulative incidence of late-onset cs-CMVi was significantly lower in the CMV-CMI-guided group compared with the fixed-duration group (9.7% vs 24.8%, P = .019). The CMV-CMI-guided group also had improved overall survival (89.1% vs 77.1%, P = .04) and relapse-free survival (88.4% vs 76.8%, P = .01). Patients were divided into high-risk (n = 36) and low-risk (n = 146) groups, based on risk factors for late-onset cs-CMVi. Among high-risk individuals, the cumulative incidence of late-onset cs-CMVi was significantly lower in the CMV-CMI-guided group than in the fixed-duration group (12.5% vs 46.3%, P = .04).
Conclusions:
CMV-CMI-guided letermovir prophylaxis may help reduce the risk of late-onset cs-CMVi, particularly in individuals at high risk.
Clinical Trials Registration:
NCT06708130.
More Related Videos
10:24Automated Cell Enrichment of Cytomegalovirus-specific T cells for Clinical Applications using the Cytokine-capture System
Published on: October 5, 2015
11:18Expanding Cytotoxic T Lymphocytes from Umbilical Cord Blood that Target Cytomegalovirus, Epstein-Barr Virus, and Adenovirus
Published on: May 7, 2012
Related Concept Videos
01:22Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
01:21Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
01:40Cell-mediated Immune Responses
01:27Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...